Vancouver, British Columbia--(Newsfile Corp. - March 1, 2018) - NeutriSci International Inc. (TSXV: NU) (OTCQB: NRXCF) (FSE: 1N9) (the "Company" or "NeutriSci") the innovator and pioneer behind neuenergy®, is pleased to announce the filing of a new U.S. provisional patent application (United States Provisional Patent No. 62/628,735; Compositions Comprising Co-crystals of Stilbenoids and Cannabinoids) relating to compositions comprising pterostilbene and other stilbenoids in formulations which improve the dissolution rate and bioavailability of cannabinoid compounds.
Cannabinoids are a group of compounds which are ligands to cannabinoid receptors (CB1, CB2) found in the human body. Cannabinoids have been reported to counter the symptoms of a broad range of conditions including multiple sclerosis and other forms of muscular spasm, including uterine and bowel cramps; movement disorders; pain, including migraine headache; glaucoma, asthma, inflammation, insomnia, and high blood pressure. There may also be utility for cannabinoids as an oxytoxic, anxiolytic, anti-convulsive, anti-depressant and anti-psychotic agent, or anti-cancer agent, as well as an appetite stimulant.
As outlined in the patent application, the invention is a process for preparing an oral dosage form containing a cannabinoid and a stilbenoid or a derivative thereof, the process comprising: mixing and/or bonding a cannabinoid oil with the stilbenoid or the derivative thereof and generating co-crystals of the cannabinoid and the stilbenoid; lyophilizing the co-crystals to form a powder; adding a solubility enhancing agent to the powder; and formulating the powder into the oral dosage form.
Mr. Glen Rehman, President of NeutriSci, stated, "This is a major announcement, representing a giant move forward for NeutriSci. This invention and provisional patent application provides NeutriSci with a significant step towards the development of a solid drug delivery platform. We intend to continue to strengthen our intellectual property portfolio as we believe our IP portfolio to be a valued asset moving forward."
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
NeutriSci International Inc.
Tel: (403) 264-6320
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production, and formulation of nutraceutical products. NeutriSci is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company's natural energy and focus supplement that has at its core, the beneficial effects of blueberries.
Neuenergy® contains a unique patented combination of blueberries (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit www.getneuenergy.com.
Ambarii, a wholly owned subsidiary of NeutriSci, NeutriSci is expanding its reach into the burgeoning cannabinoid industry.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure, or prevent any disease.